AVTX vs PH · P/E 0.0, rev $441.0K vs P/E 28, rev $19.85B
Avalo Therapeutics Inc (AVTX) versus Parker-Hannifin Corporation (PH) — a side-by-side from cached financials, not a winner call.
Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on US.
Parker-Hannifin Corporation (PH) is a specialty industrial machinery company listed on US.
Latest reported AVTX revenue for 2024-12-31 was $441.0K. Net income was -$35.1M. Revenue was down 77.1% from 2023-12-31 to 2024-12-31. AVTX currently screens at market cap $51.5M and trailing P/E 0.0.
Latest reported PH revenue for 2025-06-30 was $19.85B. Net income was $3.53B. PH currently screens at market cap $91.89B and trailing P/E 27.7.
AVTX currently screens at market cap $51.5M and trailing P/E 0.0. PH currently screens at market cap $91.89B and trailing P/E 27.7.
Not investment advice. Open the AVTX and PH stock pages for the full models.
Not investment advice.